How does the Recurrence Score® result correlate with a patients likelihood of distant recurrence?
The Oncotype DX Assay Recurrence Score result is provided on a scale of 0 to 100. Each Recurrence Score result is calculated based on the results of the patient’s tumor gene expression profile. For node-negative, estrogen-receptor-positive breast cancer patients treated with tamoxifen, the Recurrence Score result correlates to a specific likelihood of distant recurrence as observed in the clinical validation study as well as likelihood of chemotherapy benefit (CMF/MF). For node-positive, estrogen-receptor-positive post-menopausal patients treated with tamoxifen, the report form now includes the SWOG 8814 study which evaluated risk of recurrence or death vs the Recurrence Score result (both prognosis and likelihood of chemotherapy benefit [CAF]).
